I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.


This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here



It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

RUA Life Sciences (RUA)

RUA Life Sciences

Completion of Property Purchase
RNS Number : 7665R
RUA Life Sciences PLC
02 July 2020


RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Completion of Property Purchase

RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM), is pleased to announce completion of the purchase of a factory unit and associated cleanroom facilities at Skye Road Prestwick.

In the Company's circular to shareholders dated 11 March 2020 (the "Circular"), it was disclosed that RUA Medical Devices Limited ("RUA"), a wholly owned subsidiary of the Company, would purchase the property at 6 Skye Road, Shawfarm Industrial Estate, Prestwick (the "Property") from Glenavon Estates (a partnership of David Richmond's wife and daughter), for a consideration of £205,000 (excluding VAT), to be satisfied in cash. In addition, the Offer to Sell (as defined in the Circular) gives RUA the option, over a two year period from the date of transfer of title to RUA, to sell the Property back to Glenavon Estates for a consideration of £203,980 (excluding VAT) in cash. The purchase of the Property was a related party transaction given the relationship between the vendor and David Richmond, the Group CEO of RUA Life Sciences, and, consequently shareholder approval was obtained at the Company's general meeting held on 31 March 2020. The purchase of the Property completed on 30 June 2020 when title transferred to RUA.

Bill Brown, Chairman of RUA Life Sciences, commented : "I am pleased that RUA now owns all of its production facilities and we have been able to reduce our ongoing cash costs as the annual maintenance costs of servicing the loan taken out to finance the purchase is less than the commercial rental value of the property."


For further information contact:


RUA Life Sciences

Bill Brown, Chairman                                  Tel: +44 (0) 77 3071 8296                                   


Shore Capital 

Tom Griffiths/David Coaten                        Tel: +44 (0)20 7408 4080



About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-EonTM, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.


Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.


The Group's four business units are:

RUA Medical :

End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.

RUA Biomaterials :

Licensor of Elast-EonTM polymers to the medical device industry.

RUA Vascular:

Development of large bore polymer sealed grafts and soft tissue patches.

RUA Structural Heart :

Development of tri leaflet polymeric heart valves.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close